Solid tumor patients with NTRK fusion mutations experience “robust and durable responses” to treatment with larotrectinib, but those with other types of NTRK alterations derive “limited benefit” from the selective TRK inhibitor, investigators say.

Larotrectinib will be available either as on oral solution (20 mg/mL) or as capsules (25 and 100 mg).

medwireNews : The US FDA has granted approval for use of atezolizumab alongside chemotherapy for some patients with nonsquamous non-small-cell lung cancer (NSCLC), while larotrectinib may now be used against solid tumors with the neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion.

Preliminary findings for larotrectinib suggest that the agent may offer an effective tumor type-agnostic treatment for adults and children presenting with tropomyosin receptor kinase fusions.

Entrectinib is the second agent, after larotrectinib , to receive a positive decision from the Committee for Medicinal Products for Human on a tumor-agnostic basis.

In the absence of other satisfactory treatment options, the panel “strongly” recommends that clinicians should give PD-1 inhibitor therapy, such as pembrolizumab, to patients who test positive for MSI/dMMR, and the TRK inhibitors larotrectinib or entrectinib to those with NTRK fusions.

. © 2019 Springer Healthcare part of the Springer Nature group AACR Annual Meeting 2019; Atlanta, Georgia, USA: 29 March–3 April See also: LOXO-195 could be an option for tumors resistant to first-generation TRK inhibitors Larotrectinib ‘potential standard of care’ for adult, pediatric TRK fusion tumors Atezolizumab, larotrectinib approvals announced by FDA

. © 2019 Springer Healthcare part of the Springer Nature group AACR Annual Meeting 2019; Atlanta, Georgia, USA: 29 March–3 April See also: Larotrectinib ‘potential standard of care’ for adult, pediatric TRK fusion tumors Atezolizumab, larotrectinib approvals announced by FDA

. © 2019 Springer Healthcare part of the Springer Nature group Lancet Oncol 2019; doi:10.1016/S1470-2045(19)30167-6 Lancet Oncol 2019; doi: 10.1016/S1470-2045(19)30148-2 See also: Atezolizumab boosts survival in metastatic nonsquamous NSCLC Atezolizumab, larotrectinib approvals announced by FDA

. © 2019 Springer Healthcare part of the Springer Nature group Lancet Respir Med 2019; doi:10.1016/S2213-2600(19)30084-0 See also: Atezolizumab, larotrectinib approvals announced by FDA

. © 2019 Springer Healthcare part of the Springer Nature group See also:  Atezolizumab, larotrectinib approvals announced by FDA Atezolizumab receives NICE recommendation for NSCLC Atezolizumab receives positive opinion for advanced urothelial cancer, NSCLC